Patient Perception of Vehicle and How This Influences Adherence to Topical Treatment Regimens

Steven R. Feldman MD, FAAD; Rhonda Schreiber BSN, MS; Kaytiana Crane BS; Madelyn Comito

INTRODUCTION

- Psoriasis can lead to long-lasting psychological, social, and physical complications.
- The majority of cases can be treated with topical therapies, however poor adherence negatively impacts treatment success.1,2
- Vehicle attribute influence adherence.3
- Calcipotriene foam, 0.005%, is a safe and effective sterol-based vitamin D3 analog for plaque psoriasis of the scalp and body.4
- We assessed patient preference for attributes of both active and vehicle foams and how these preferences impacted patient intentions to comply with prescribed treatment plans.

METHODS

- Two identically designed, 8-week, blinded, multicenter, parallel group clinical trials were conducted with 659 subjects with mild to moderate plaque type psoriasis randomized in a 2:1 ratio to topical calcipotriene foam, 0.005%, (n=437) or vehicle foam (n=222).
- Subjects ≥ 12 years with mild to moderate plaque psoriasis involving 2-20% of body surface areas (BSA).
- Foam was applied morning and evening or 8 weeks to lesions on the body, using the smallest amount of the treatment plan.
- At the final study visit a patient questionnaire was administered regarding formulation attributes, preference for treatment vehicle, and intent to adhere to treatment instructions.
- Questionnaire results from both Phase III trials have been integrated for analysis and presentation here.

RESULTS

Please rate the following qualities of the foam, compared to the other skin medicines you have used in the past:

- BETTER THAN PREVIOUSLY TRIED MEDICATIONS
- MUCH BETTER
- MUCH WORSE
- SAME
- MUCH BETTER

Please rate the foam on each of the following: easy to apply, spreadability, absorbs quickly, lack of stickiness, fragrance free, does not feel greasy, lack of residue, and moisturizing:

- BOTH THE ACTIVE FOAM AND VEHICLE RATED EXCELLENT OR GOOD WITH GREATER THAN 80% OF SUBJECTS ON ALL FORMULATION AND APPLICATION ATTRIBUTES, EXCEPT MOISTURIZING, WHERE 55% OF SUBJECTS RATED THE FOAM AS EXCELLENT OR GOOD.

- BOTH THE ACTIVE FOAM AND VEHICLE RATED EXCELLENT OR GOOD WITH GREATER THAN 80% OF SUBJECTS ON ALL FORMULATION AND APPLICATION ATTRIBUTES, EXCEPT MOISTURIZING, WHERE 55% OF SUBJECTS RATED THE FOAM AS EXCELLENT OR GOOD.

CONCLUSIONS

Difficulties with patient adherence to previously available topical formulations of calcipotriene are well documented and prescribers have long sought ways to improve patient compliance with prescribed treatment regimens. Patients have positive perceptions of the foam vehicle attributes, strong preference for the foam vehicle compared to previously tried medications, and a 22% greater reported likelihood of complying with prescribed treatment where foam is included. The foam vehicle may lead to better compliance and outcomes for patients suffering from psoriasis.

REFERENCES


DISCLOSURES: Dr. Feldman is a paid consultant at Mayne Pharma. Mrs. Schreiber, Ms. Crane, and Ms. Comito are employees of Mayne Pharma. This presentation was sponsored by Mayne Pharma.